Basit öğe kaydını göster

dc.contributor.authorDuzgun, N
dc.contributor.authorAyaslioglu, E
dc.contributor.authorTutkak, H
dc.contributor.authorAydintug, OT
dc.date.accessioned2020-06-25T17:40:54Z
dc.date.available2020-06-25T17:40:54Z
dc.date.issued2005
dc.identifier.issn0172-8172
dc.identifier.issn1437-160X
dc.identifier.urihttps://doi.org/10.1007/s00296-003-0400-6
dc.identifier.urihttps://hdl.handle.net/20.500.12587/3582
dc.descriptionWOS: 000226665600001en_US
dc.descriptionPubMed: 14600787en_US
dc.description.abstractSerum levels of proinflammatory cytokines interleukin-1 beta (IL-1beta), tumor necrosis factor alpha, (TNF-alpha), and their inhibitors, IL-1 receptor antagonist (IL-1ra) and soluble TNF receptor 1 (sTNFR1), were determined by enzyme-linked immunosorbent assay in 104 patients with Behcet's disease (65 active, 39 inactive) and 40 healthy controls. The levels of IL-1beta and IL-1ra were significantly higher in both active and inactive patients than in control subjects (P < 0.01 and P < 0.01, respectively). The concentrations of TNF-alpha and sTNFR1 were found to be higher in active patients than in controls (P < 0.01 and P < 0.001, respectively). There were no significant differences in the serum levels of these cytokines and their inhibitors between active and inactive patients. Significant increases in mean C-reactive protein level and erythrocyte sedimentation rate were found in patients with active vs inactive disease (P < 0.001 and P < 0.05, respectively). C-reactive protein values correlated with erythrocyte sedimentation rate but not with cytokines or their inhibitors. Our conclusion is that elevated serum TNF-alpha and sTNFR1 seem to be important inflammatory mediators in Behcet's disease. The statistically significant increase in these levels may arise from the severity of inflammation in the tissue or organ involved.en_US
dc.language.isoengen_US
dc.publisherSpringer Heidelbergen_US
dc.relation.isversionof10.1007/s00296-003-0400-6en_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBehcet's diseaseen_US
dc.subjectinterleukin-1en_US
dc.subjectinterleukin-1 receptor antagonisten_US
dc.subjectsoluble tumoren_US
dc.subjectnecrosis factor receptor 1en_US
dc.subjecttumor necrosis factoren_US
dc.titleCytokine inhibitors: soluble tumor necrosis factor receptor 1 and interleukin-1 receptor antagonist in Behcet's diseaseen_US
dc.typearticleen_US
dc.contributor.departmentKırıkkale Üniversitesien_US
dc.identifier.volume25en_US
dc.identifier.issue1en_US
dc.identifier.startpage1en_US
dc.identifier.endpage5en_US
dc.relation.journalRheumatology Internationalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster